Indeed, combined treatment with antagonists targeting each PGD2 receptors (PTGDR), e.g., PTGDR-1 (laropiprant) and PTGDR-2 (CAY10471), was sufficient in reducing basophil recruitment to SLOs, plasmablast accumulation, autoreactive antibody production, CIC glomerular deposition, and kidney inflammation in less than 10 days, in both genetic spontaneous and inducible lupus-like nephritis mouse models (10). The gene discussed is PTGDR2; the disease is nephritis.